Initial Testing (Stage 1) of MK-8242, a Novel MDM2 Inhibitor, by the Pediatric Preclinical Testing Program

BACKGROUND: MK-8242 is an inhibitor of MDM2 that stabilizes the tumor suppressor TP53 and induces growth arrest or apoptosis downstream of TP53 induction. PROCEDURES: MK-8242 was tested against the PPTP in vitro cell line panel at concentrations from 1.0 nM to 10.0 μM and against the PPTP in vivo xe...

Full description

Saved in:
Bibliographic Details
Published in:Pediatr Blood Cancer
Main Authors: Kang, Min H., Reynolds, C. Patrick, Kolb, E. Anders, Gorlick, Richard, Carol, Hernan, Lock, Richard, Keir, Stephen T., Maris, John M., Wu, Jianwrong, Lyalin, Dmitry, Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A.
Format: Artigo
Language:Inglês
Published: 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5657425/
https://ncbi.nlm.nih.gov/pubmed/27238606
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.26064
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items